Sustained release medicinal preparation
    3.
    发明授权
    Sustained release medicinal preparation 失效
    持续释放药用制剂

    公开(公告)号:US5601844A

    公开(公告)日:1997-02-11

    申请号:US424498

    申请日:1995-05-18

    摘要: A sustained release medicinal preparation is produced by enclosing a macrocyclic compound represented by 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl)-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone or 17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone, into the fine particles generally called microspheres which arc made of biodegradable polymer. This preparation, when, for example, given by injection, appreciably improves the transferance of said macrocyclic compound into the blood. Further, this is also used as an agent suitable for topical administration.

    摘要翻译: PCT No.PCT / JP93 / 01672 Sec。 371日期1995年5月18日 102(e)日期1995年5月18日PCT提交1993年11月11日PCT公布。 公开号WO94 / 10981 日期1994年5月26日缓释药物制剂是通过将由17-烯丙基-1,14-二羟基-12- [2-(4-羟基-3-甲氧基环己基)-1-甲基乙烯基)-23表示的大环化合物, 25-二甲氧基-13,19,21,27-四甲基-11,28-二氧杂-4-氮杂三环[22.3.1.04,9]二十八-18-烯-2,3,10,16-四酮或17-乙基 - 1,14-二羟基-12- [2-(4-羟基-3-甲氧基环己基)-1-甲基乙烯基] -23,25-二甲氧基-13,19,21,27-四甲基-11,28-二氧杂-4- 氮杂三环[22.3.1.04,9]二十八烷-18-烯-2,3,10,16-四酮,形成由可生物降解的聚合物制成的通常称为微球的细颗粒。 当通过注射给予时,该制剂明显地改善了所述大环化合物向血液中的转移。 此外,这也用作适合局部给药的药剂。

    Delayed action preparation
    5.
    发明授权
    Delayed action preparation 失效
    延迟行动准备

    公开(公告)号:US5654009A

    公开(公告)日:1997-08-05

    申请号:US635556

    申请日:1996-04-22

    IPC分类号: A61K9/16 A61K9/50 A61K9/52

    摘要: The invention relates to a delayed action preparation which comprises a core comprising a drug and a swelling agent and an outer membrane comprising a biodegradable high molecular weight substance characterized in that the swelling agent is contained in a sufficient amount to cause a explosion of the outer membrane of biodegradable high molecular weight substance at a definite time after administration. This preparation provides for free control over the timing of drug release and is suited for administration not only by the oral route but also by the intramuscular, subcutaneous and other routes.

    摘要翻译: 本发明涉及延迟作用制剂,其包括包含药物和溶胀剂的核心和包含可生物降解的高分子量物质的外膜,其特征在于包含足够量的溶胀剂以引起外膜爆炸 的生物降解性高分子量物质。 该制剂提供了对药物释放时间的自由控制,并且不仅通过口服途径而且通过肌内,皮下和其它途径进行给药。

    Aerosol compositions
    6.
    发明授权
    Aerosol compositions 失效
    气溶胶成分

    公开(公告)号:US06361760B1

    公开(公告)日:2002-03-26

    申请号:US09029863

    申请日:1998-04-22

    IPC分类号: A61K912

    摘要: The use of a medium-chain fatty acid triglyceride as the dispersant in the preparation of a medicinal aerosol composition comprising tricyclic compound (I) dispersed in a liquefied hydrofluoroalkane propellant is described. When a liquefied hydrofluoroalkane is added to a kneaded premix of the tricyclic compound (I) and a medium-chain fatty acid triglyceride, the active ingredient is evenly dispersed in the liquefied hydrofluoroalkane. Therefore, by distributing a dispenser first with the kneaded premix and, then, with a liquefied hydrofluoroalkane under cooling or elevated pressure, there can be provided a medicinal aerosol composition having an improved uniformity of content of the active ingredient.

    摘要翻译: 描述了使用中链脂肪酸甘油三酸酯作为分散剂来制备包含分散在液化氢氟烷烃推进剂中的三环化合物(I)的药用气溶胶组合物。 当将液化氢氟烷烃加入到三环化合物(I)和中链脂肪酸甘油三酯的捏合预混物中时,活性成分均匀分散在液化氢氟烷烃中。 因此,首先通过在搅拌的预混物中分配分配器,然后在冷却或升高的压力下用液化氢氟烷烃分配分配器,可以提供具有改善的活性成分含量均匀性的药用气溶胶组合物。

    Aerosol compositions
    7.
    发明授权
    Aerosol compositions 失效
    气溶胶成分

    公开(公告)号:US06524556B2

    公开(公告)日:2003-02-25

    申请号:US09994702

    申请日:2001-11-28

    IPC分类号: A61K912

    摘要: The use of a medium-chain fatty acid triglyceride as the dispersant in the preparation of a medicinal aerosol composition comprising tricyclic compound (I) dispersed in a liquefied hydrofluoroalkane propellant is described. When a liquefied hydrofluoroalkane is added to a kneaded premix of the tricyclic compound (I) and a medium-chain fatty acid triglyceride, the active ingredient is evenly dispersed in the liquefied hydrofluoroalkane. Therefore, by distributing a dispenser first with the kneaded premix and, then, with a liquefied hydrofluoroalkane under cooling or elevated pressure, there can be provided a medicinal aerosol composition an improved uniformity of content of the active ingredient.

    摘要翻译: 描述了使用中链脂肪酸甘油三酸酯作为分散剂来制备包含分散在液化氢氟烷烃推进剂中的三环化合物(I)的药用气溶胶组合物。当将液化氢氟烷烃加入到三环化合物的捏合预混物中时 (I)和中链脂肪酸甘油三酸酯,活性成分均匀分散在液化氢氟烷烃中。因此,首先通过在搅拌的预混物中分配分配器,然后在冷却或升高的压力下用液化氢氟烷烃分配分配器, 提供药物气溶胶组合物,改善活性成分含量的均匀性。

    Liposome preparation
    9.
    发明授权
    Liposome preparation 失效
    脂质体制备

    公开(公告)号:US5152999A

    公开(公告)日:1992-10-06

    申请号:US680923

    申请日:1991-04-05

    IPC分类号: A61K9/127

    摘要: The present invention relates to liposome preparations. In particular, the present invention relates to Adriamycin-entrapped liposome preparations comprising cholesterol derivatives having a negative charge as a liposome membrane constituent. Adriamycin-entrapped liposome preparations have many uses in the medical field such as maintaining high Adriamycin blood levels over a long period of time and reducing systemic toxicity, for example.

    摘要翻译: 本发明涉及脂质体制剂。 特别地,本发明涉及包含具有负电荷的胆固醇衍生物作为脂质体膜成分的阿霉素截留的脂质体制剂。 阿霉素包埋的脂质体制剂在医学领域中具有许多用途,例如在长时间内维持高阿霉素血液水平并降低全身毒性。

    External skin treatment agent composition containing isocarbacyclins as
active ingredient
    10.
    发明授权
    External skin treatment agent composition containing isocarbacyclins as active ingredient 失效
    含有异卡巴菌素作为活性成分的外用皮肤治疗剂组合物

    公开(公告)号:US5656663A

    公开(公告)日:1997-08-12

    申请号:US313146

    申请日:1994-12-28

    IPC分类号: A61K31/557 A61K31/215

    摘要: An external skin treatment agent composition containing an active ingredient comprising a prostacyclin, and/or its optical isomer, having the formula (I): ##STR1## (wherein, R.sup.1 is a hydrogen atom, a straight chain or branched alkyl group of C.sub.1 to C.sub.10, or one equivalent of a cation, R.sup.2 is a substitutable C.sub.1 to C.sub.10 straight chain or branched alkyl group or substitutable C.sub.1 to C.sub.10 straight chain or branched alkenyl group or alkinyl group, R.sup.3 is a straight chain alkyl group of C.sub.1 to C.sub.5, and R.sup.4 and R.sup.5 are independently a hydroxyl group or formula: ##STR2## (where, R.sup.6 is a C.sub.1 to C.sub.5 straight chain or branched alkyl group)) and a carrier.

    摘要翻译: PCT No.PCT / JP94 / 00163 Sec。 371日期1994年12月28日第 102(e)日期1994年12月28日PCT 1994年2月3日PCT PCT。 公开号WO94 / 17805 日期:1994年8月18日含有包含前列环素的活性成分和/或其旋光异构体的具有式(I)的外用皮肤治疗剂组合物:其中R1是氢原子,直链 C1至C10的链或支链烷基或一当量阳离子,R2为可取代C1至C10直链或支链烷基或可取代C1至C10直链或支链烯基或炔基,R3为直链 C1〜C5的烷基,R4和R5分别独立地为羟基或式:其中R6为C1-C5直链或支链烷基)和载体。